Hans Edgar Bishop - Jun 14, 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Matthew Lang, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/17/2024, 04:17 PM
Previous filing
Jun 7, 2024
Next filing
Jul 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LYEL Common Stock 4.69M Jun 14, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +130K $0.00 130K Jun 14, 2024 Common Stock 130K $2.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date.